CIK 0001825367
RYZB RayzeBio, Inc.
Insider trading from SEC Form 4. Last filing Feb 28, 2024.
In brief
RayzeBio, Inc. (RYZB) has 18 SEC Form 4 filings on file from 11 insiders, the latest filed on Feb 28, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at RayzeBio, Inc., scored.
Transactions
Every row filed, 37 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 26, 2024 | Viking Global Investors LP owner | JOther Common Stockindirect: See Explanation of Responses | -4,899,144 | - | - | 0 | Feb 28, 2024 |
| Feb 26, 2024 | Viking Global Investors LP owner | JOther Common Stockindirect: See Explanation of Responses | -4,899,144 | - | - | 0 | Feb 28, 2024 |
| Feb 26, 2024 | Viking Global Investors LP owner | JOther Common Stockindirect: See Explanation of Responses | -1,743,556 | - | - | 0 | Feb 28, 2024 |
| Feb 26, 2024 | Viking Global Investors LP owner | JOther Common Stockindirect: See Explanation of Responses | -1,743,556 | - | - | 0 | Feb 28, 2024 |
| Feb 26, 2024 | Richard A. Heyman director | DDisposition to issuer Common Stock | -367,446 | $62.50 | $23M | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Maha Katabi director | DDisposition to issuer Common Stockindirect: See footnote | -1,209,764 | $62.50 | $76M | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Mary Tagliaferri director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -73,731 | - | - | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Timothy Van Hauwermeiren director | DDisposition to issuer Stock Option (Right to Buy)derivative | -48,628 | - | - | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Arvind Kush CHIEF FINANCIAL OFFICER | DDisposition to issuer Common Stock | -78,433 | $62.50 | $4.9M | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Kenneth Song PRESIDENT AND CHIEF EXECUTIVE | DDisposition to issuer Common Stockindirect: By trust | -1,622,968 | $62.50 | $101M | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Christy J. Oliger director | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -114,579 | - | - | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Yi Larson director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -59,399 | - | - | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Angie You director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -73,731 | - | - | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Susan Moran CHIEF MEDICAL OFFICER | DDisposition to issuer Common Stock | -323,455 | $62.50 | $20M | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Mary Tagliaferri director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -40,848 | - | - | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Kenneth Song PRESIDENT AND CHIEF EXECUTIVE | DDisposition to issuer Employee Stock Option (right to buy)derivativeindirect: By trust | -758,607 | - | - | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Susan Moran CHIEF MEDICAL OFFICER | DDisposition to issuer Employee Stock Option (right to buy)derivative | -60,757 | - | - | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Yi Larson director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -14,332 | - | - | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Angie You director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -40,848 | - | - | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Arvind Kush CHIEF FINANCIAL OFFICER | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -301,745 | - | - | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Maha Katabi director | DDisposition to issuer Common Stockindirect: See footnote | -1,209,764 | $62.50 | $76M | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Susan Moran CHIEF MEDICAL OFFICER | DDisposition to issuer Employee Stock Option (right to buy)derivative | -77,805 | - | - | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Yi Larson director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -40,848 | - | - | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Arvind Kush CHIEF FINANCIAL OFFICER | DDisposition to issuer Employee Stock Option (right to buy)derivative | -149,777 | - | - | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Kenneth Song PRESIDENT AND CHIEF EXECUTIVE | DDisposition to issuer Employee Stock Option (right to buy)derivativeindirect: By trust | -114,763 | - | - | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Maha Katabi director | DDisposition to issuer Stock Option (right to buy)derivative | -18,235 | - | - | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Susan Moran CHIEF MEDICAL OFFICER | DDisposition to issuer Employee Stock Option (right to buy)derivative | -194,514 | - | - | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Kenneth Song PRESIDENT AND CHIEF EXECUTIVE | DDisposition to issuer Employee Stock Option (right to buy)derivativeindirect: By trust | -480,000 | - | - | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Arvind Kush CHIEF FINANCIAL OFFICER | DDisposition to issuer Employee Stock Option (right to buy)derivative | -164,000 | - | - | 0 | Feb 27, 2024 |
| Feb 26, 2024 | Susan Moran CHIEF MEDICAL OFFICER | DDisposition to issuer Employee Stock Option (right to buy)derivative | -164,000 | - | - | 0 | Feb 27, 2024 |
| Jan 22, 2024 | Susan Moran CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +30,875 | $3.24 | $100k | 322,647 | Feb 6, 2024 |
| Jan 22, 2024 | Susan Moran CHIEF MEDICAL OFFICER | MOption exercise Employee Stock Option (right to buy)derivative | -30,875 | $0.00 | $0 | 60,757 | Feb 6, 2024 |
| Nov 17, 2023 | Maha Katabi director | AGrant or award Stock Option (right to buy)derivative | +18,235 | $0.00 | $0 | 18,235 | Nov 17, 2023 |
| Nov 17, 2023 | Arvind Kush Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +164,000 | $0.00 | $0 | 164,000 | Nov 17, 2023 |
| Nov 17, 2023 | Susan Moran Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +164,000 | $0.00 | $0 | 164,000 | Nov 17, 2023 |
| Nov 17, 2023 | Kenneth Song President and Chief Executive | AGrant or award Stock Option (right to buy)derivativeindirect: By trust | +480,000 | $0.00 | $0 | 480,000 | Nov 17, 2023 |
| Nov 1, 2023 | Timothy Van Hauwermeiren director | AGrant or award Stock Option (right to buy)derivative | +48,628 | $0.00 | $0 | 48,628 | Nov 1, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Richard A. Heymandirector
- Maha Katabidirector, owner
- Arvind KushCHIEF FINANCIAL OFFICER
- Yi Larsondirector
- Susan MoranCHIEF MEDICAL OFFICER
- Christy J. Oligerdirector
- Kenneth SongPRESIDENT AND CHIEF EXECUTIVE
- Mary Tagliaferridirector
- Viking Global Investors LPowner
- Timothy Van Hauwermeirendirector
- Angie Youdirector
Questions about RYZB
Answered from the filings on this page, as of the latest one.
Are insiders buying RYZB?
No. In the last 90 days no insider at RayzeBio, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade RYZB on the open market?
No open-market trade has been scored at RayzeBio, Inc.. The latest Form 4 on file was filed on Feb 28, 2024 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at RayzeBio, Inc.?
11 people have filed a Form 4 at RayzeBio, Inc., among them Richard A. Heyman (director), Maha Katabi (director and 10% owner), Arvind Kush (CHIEF FINANCIAL OFFICER). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.